Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px
Organisation › Details

OSE Immunotherapeutics S.A.

OSE Pharma is a European cancer immunotherapy company with a multi-epitope technology named Memopi® that directs the body’s immune system to generate a specific cytotoxic T response to prevent cancer cell growth. OSE Pharma’s lead product, Tedopi®, combines 10 “neo-epitopes” directed against five tumour associated antigens. In its most advanced application it is about to enter a pivotal Phase III study in patients with advanced non-small cell lung cancer (NSCLC) who express HLA-A2 and who have failed first line therapy. Tedopi® has orphan drug status in the USA and is considered as personalised medicine in Europe in HLA-A2 positive patients. OSE Pharma is also planning a new Phase II clinical trial in combination with another immunotherapy treatment in NSCLC. Tedopi® targets five tumour associated antigens (TAA), selected because their presence is linked to a poor prognosis and the severity of various cancers. Tedopi® contains a total of ten optimised epitopes, or “neo- epitopes”, designed on the binding of HLA-A2 and TCR. These neo-epitopes generate strong specific T cytotoxic responses that fight cancer and prevent tumour escape. (ISIN : FR0012127173 ; Mnémo : OSE). *

 

Period Start 2014-09-21 existent
Period End 2016-05-31 merged
  Group OSE Immunotherapeutics (Group)
  Today OSE Pharma S.A.
  Predecessor Effimune S.A.S.
Products Industry Memopi® multi-epitope technology
  Industry 2 Tedopi® cancer immunotherapy
Persons Person Costantini, Dominique (OSE Pharma 201504 CEO + Co-founder + former CEO + Co-founder of BioAlliance Pharma in 1997)
  Person 2 Peyroles, Alexis (OSE Pharma 201504 CFO)
     
Region Region Nantes
  Country France
  Street 22 boulevard Benoni Goullin
  City 44200 Nantes
  Tel +33-2-2829-1010
    Address record changed: 2017-02-10
     
Basic data Employees n. a.
  Currency EUR
  Profit -5,584,000 (2015-12-31)
  Cash 15,131,000 (2015-12-31)
     
    * Document for �About Section�: OSE Pharma S.A.. (4/29/15). "Press Release: 2014 Key Steps and 2015 Outlook. 2014 Annual Results [Not for distribution directly or indirectly in the United States, Canada, Australia or Japan]". Paris.
     
   
Record changed: 2018-09-12

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for OSE Immunotherapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top